CSL vs ResMed: Which ASX Healthcare Giant Is a Better Buy?

CSL and ResMed are strengthening their businesses through new partnerships, product innovation and strategic investments while focusing on growth, operational efficiency and long-term shareholder value

Investors looking to identify the best ASX stocks to buy now can explore the latest market insights, stock analysis and investment opportunities from Veye Research. Explore the latest ASX market insights.

CSL Ltd (ASX: CSL)

CSL Ltd (ASX: CSL) is a global biopharmaceutical company with a 100 year history. It develops plasma therapies, vaccines and medicines for rare and serious diseases worldwide.

Expansion in collaboration between CSL and Haemonetics Corporation was announced on October 8, 2026. The firm intends to implement the new plasmapheresis system of Haemonetics in all its plasma collection centers in America by the close of 2027. It has also entered into an agreement with Terumo BCT, who supply the existing Rika system of the firm. The move aims to improve the efficiency of its plasma collection network.

On 5 October 2026, CSL entered an exclusive agreement with Alentis Therapeutics to develop and promote lixudebart for rare kidney and liver diseases. The treatment is being tested in a Phase 2 trial for AAV-RPGN and may also be developed for FSGS and PSC. CSL will pay US$355 million initially, while Alentis may receive up to US$1.2 billion in commercial milestone payments. CSL will also fund the planned clinical trials. Once launched, global profits will be shared between CSL and Alentis in a 55:45 ratio.

On 1 September 2026, CSL announced agreements with the U.S. government to make its medicines available to Medicaid at prices similar to those in other developed countries. New treatments will follow similar pricing for all U.S. payers. CSL also agreed to expand its manufacturing facility in Kankakee, Illinois, through a planned US$1.5 billion investment. CSL expects no major financial impact from these agreements in FY27.

ResMed Inc. (ASX: RMD)

ResMed Inc. (ASX: RMD), on 30 October 2026, announced its first quarter FY2027 results. The company’s revenue grew 6% to US$1.4b. Earnings per share increased 23% to US$2.92. The adjusted earnings per share rose 14% to US$2.91. It also returned more than US$1 billion to shareholders through dividends and share buybacks.

During the quarter, RMD completed the sale of MatrixCare and introduced the AirTouch F40 fabric-based CPAP mask in the U.S. RMD also entered into partnership with Eight Sleep that enabled their tech to integrate with the data of ResMed's sleep in the United States and Australia.

The company also recorded growth across its main businesses. Revenue from the Americas increased 7%, while its business in other parts of the world grew 8%. Revenue from its Residential Care Software business also increased 5%.

ResMed's adjusted gross profit margin improved to 62.5%, up 0.5% points from last year. Cash generated from daily business operations reached US$422 million. Free cash flow stood at US$374 million. The company continued investing in new products and business growth while returning money to shareholders.

(Source: Company Report)